Abstract:The transient receptor potential vanilloid type 1 (TRPV1), a non-selective cation channel, is known for its essential role in the pathogenesis of various pain conditions such as nerve damage induced hyperalgesia, diabetic neuropathy and cancer pain. Therefore, TRPV1 is considered as a promising target for the development of new anti-inflammatory and analgesic drugs. In the present study, a theoretical study on the functionalities of the molecular interactions between 236 active ligands and TRPV1 was carried out, using three-dimensional quantitative structure-activity relationships (3D-QSAR), molecular docking and molecular dynamics (MD) simulation approaches. The ligand-based CoMSIA model (obtained by use of a random division method for splitting the training and test sets) exhibits optimum predictivity (Q(2) = 0.522, R(ncv)(2) = 0.935, R(pred)(2) = 0.839). The results show that the models are useful tools for the prediction of the test sets as well as newly designed structures against TRPV1 activity. In addition, to verify the rationality of the random division method for splitting the dataset, we also used a self-organizing map (SOM) division approach for establishing the QSAR models. Interestingly, the obtained optimal CoMSIA model based on the SOM division exhibits almost the same proper statistical results (Q(2) = 0.521, R(ncv)(2) = 0.929, R(pred)(2) = 0.829) as the random division-derived model, proving the reasonability of both division methods for building the models. The contour plots of molecular fields along with docking and MD simulation have identified several key structural requirements responsible for the activity. The present work provides extremely useful guidelines for future structural modifications of this class of compounds towards the development of superior TRPV1 antagonists. The new computational insights presented in this study are expected to be valuable for the guideline and development of new potent TRPV1 antagonists.

Novel phenylpiperazine derivatives as potent transient receptor potential vanilloid 1 antagonists

Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists

Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects in Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core.

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects (adv. Sci. 17/2021)

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

Novel dual-target μ‐opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management

Progress in the development of TRPV1 small-molecule antagonists: Novel Strategies for pain management

Design, synthesis, and analgesia evaluation of novel Transient Receptor Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD)

Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

Discovery of a novel series of pyridone amides as Na V 1.8 inhibitors

Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

Discovery of first-in-class highly selective TRPV1 antagonists with dual analgesic and hypoglycemic effects

Discovery of selective Na V 1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain

Discovery of 3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-n-phenylpiperidine-1-carboxamide As Novel Potent Analgesic.